Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai Europe, a European subsidiary of Eisai, has launched the novel once daily anti-epileptic Zebinix (eslicarbazepine acetate) in the UK as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation.
Subscribe to our email newsletter
The company said that Zebinix (eslicarbazepine acetate) which was launched in 1965 offers patients seizure control.
Patients also report improvements in health-related quality of life measures such as seizure worry and cognitive function as well as improvement in the MADRS (Montgomery-Asberg Depression Rating Scale) depressive symptoms scale.
Reportedly, the three phase III double-blind, randomised placebo-controlled trials demonstrated the efficacy, safety and tolerability of eslicarbazepine acetate (ESL) in 1,049 adult patients with partial onset seizures.
The company claims that in these studies eslicarbazepine acetate demonstrated reductions in seizure frequency and increases in responder rates.
These studies also demonstrated that patients continued to take eslicarbazepine acetate with retention rates ranging from 68-79% at one year.